Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective evaluation of the new Dutch vancomycin dosing guideline in neonates
NL-OMON42496Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2016
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vancomycin in bacterial disease, sponsored by Amsterdam University Medical Center. Primary endpoints: Therapeutic first vancomycin trough level, Subtherapeutic first vancomycin trough level and 1 more. Started Mar 2016; status: active, not recruiting.
02
Drugs
vancomycin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON42496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42496.